Emerging role of matrix metalloproteinases in the pathophysiology of cardiac diseases

European Journal of Clinical Investigation

Volumn 32, Issue 5, 2002, Pages 291-294

  Díez, Javier ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; COLLAGEN TYPE 4; COLLAGENASE; COLLAGENASE 3; CYSTEINE PROTEINASE; CYTOKINE; FIBRILLAR COLLAGEN; FIBRONECTIN; GELATINASE A; GELATINASE B; GLYCOPROTEIN; GLYCOSAMINOGLYCAN; GROWTH FACTOR; HORMONE; INTERSTITIAL COLLAGENASE; LAMININ; LISINOPRIL; LOSARTAN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; METALLOPROTEINASE; NEUTROPHIL COLLAGENASE; PROTEOGLYCAN; SERINE PROTEINASE; STROMELYSIN; STROMELYSIN 2; STROMELYSIN 3; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA1; VITRONECTIN;

AMINO ACID SEQUENCE; ANTIHYPERTENSIVE THERAPY; BIOPSY; CELL FUNCTION; CORRELATION ANALYSIS; CYTOKINE RELEASE; DIASTOLE; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; ENZYMATIC DEGRADATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME INHIBITION; ENZYME SPECIFICITY; ENZYME STRUCTURE; ESSENTIAL HYPERTENSION; EXTRACELLULAR MATRIX; FIBROBLAST; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; HEART DILATATION; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; INFLAMMATORY CELL; MESENCHYME; NONHUMAN; NOTE; PARENCHYMA; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN METABOLISM; PROTEIN SYNTHESIS; REGULATORY MECHANISM; TISSUE REPAIR; TISSUE WATER; TRANSGENIC MOUSE;

EXTRACELLULAR MATRIX; HEART DISEASES; HUMANS; METALLOENDOPEPTIDASES; TISSUE INHIBITOR OF METALLOPROTEINASES; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 0037003368     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2002.00980.x     Document Type: Note

References (37)

1. Shapiro SD. Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Curr Opin Cell Biol 1998;10:602-8.
2. Spinale FG, Coker ML, Heung LJ, Bond BR, Gunasinghe HR, Etoh T, et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 2000;102:1944-9.
3. Denhardt DT, Feng B, Edwards DR, Cocuzzi ET, Malyankar UM. Tissue inhibitor of metalloproteinases (TIMP aka EPA): Structure, control of expression and biological functions. Pharmacol Ther 1993;59:329-41.
4. Montfort I, Perez-Tamayo R. The distribution of collagenase in normal rat tissues. J Histochem Cytochem 1975;23:910-20.
5. Cleutjens JPM, Kandala JC, Guarda E, Guntaka RV, Weber KT. Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol 1994;27:1281-92.
6. Coker MS, Thomas CV, Doscher MA. Matrix metalloproteinase expression and activity in adult ventricular myocytes: Influence of basement membrane adhesion. Circulation 1997;96 (Suppl. 1):I-689.
7. Tyagi SC, Matsubara L, Weber KT. Direct extraction and estimation of collagenase (s) activity by zymography in microquantities of rat myocardium and uterus. Clin Biochem 1993;26:191-8.
8. Libby P, Lee RT. Matrix matters. Circulation 2000;102:1874-6.
9. Benjamin IJ. Matrix metalloproteinases: From biology to therapeutic strategies in cardiovascular disease. J Invest Med 2001;49:381-97.
10. Weber KT, Brilla CG, Janicki JS. Myocardial fibrosis: Functional significance and regulatory factors. Cardiovasc Res 1993;27:341-8.
11. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor β in human disease. N Engl J Med 2000;342:1350-8.
12. 1 develop progressive renal disease. Lab Invest 1996;74:991-1003.
13. 1 heterozygous mice. J Mol Cell Cardiol 2000;32:187-95.
14. 1 and phorbol myristate acetate on cardiac fibroblasts: Regulation of fibrillar collagen mRNAs and expression of early transcription factors. Circ Res 1991;69:483-90.
15. Chen MM, Lam A, Abraham JA, Schreiner GF, Joly AH. CTGF expression is induced by TGF-β in cardiac fibroblasts and cardiac myocytes: A potential role in heart fibrosis. J Mol Cell Cardiol 2000;32:1805-19.
16. Edwards DR, Murphy G, Reynolds JJ, Whitham SE, Docherty AJ, Angel P, et al. Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J 1987;6:1899-904.
17. Chua CC, Chua BH, Zhao ZY, Krebs C, Diglio C, Perrin E. Effect of growth factors on collagen metabolism in cultured human heart fibroblasts. Connect Tissue Res 1991;26:271-81.
18. 1) transgenic mice is associated with inhibition of interstitial collagenase. Eur J Clin Invest 2002;in press.
19. Sadoshima J & Izumo S. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Circ Res 1993;73:413-23.
20. Lee AA, Dillmann WH, McCulloch AD, Villarreal FJ. Angiotensin II stimulates the autocrine production of transforming growth factor-β in adult rat cardiac fibroblasts. J Mol Cell Cardiol 1995;27:2347-57.
21. Brilla CG, Matsubara L, Weber KT. Advanced hypertensive heart disease in spontaneously hypertensive rats. Lisinopril-mediated regression of myocardial fibrosis. Hypertension 1996;28:269-75.
22. 1 blockade stimulates extracellular collagen type I degradation and reverses myocardial fibrosis in spontaneously hypertensive rats. Hypertension 2000;35:1197-202.
23. Laviades C, Varo N, Díez J. Transforming growth factor β in hypertensives with cardiorenal damage. Hypertension 2000;36:517-22.
24. Weber KT. Extracellular matrix remodeling in heart failure. A role for de novo angiotensin II generation. Circulation 1997;96:4065-82.
25. Weber KT. Targeting pathological remodeling. Concepts of cardioprotection and reparation. Circulation 2000;102:1342-5.
26. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000;102:1388-93.
27. López B, Querejeta R, Varo N, González A, Larman M, Martínez-Ubago JL et al. Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation 2001;104:286-91.
28. Laviades C, Varo N, Fernández J, Mayor G, Gil MJ, Monreal I, et al. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 1998;98:535-40.
29. Dostal DE. Regulation of cardiac collagen content. Angiotensin and cross-talk with local growth factors. Hypertension 2001;37:841-4.
30. Herzog E, Gu A, Kohmoto T, Burkhoff D, Hochman JS. Early activation of metalloproteinases after experimental myocardial infarction occurs in infarct and non-infarct zones. Cardiovasc Pathol 1998;7:307-12.
31. Tyagi SC, Kumar SG, Haas SJ, Reddy HK, Voelker DJ, Hayden MR, et al. Post-transcriptional regulation of extracellular regulation of extracellular matrix metalloproteinase in human heart end-stage failure secondary to ischemic cardiomyopathy. J Mol Cell Cardiol 1996;28:1415-28.
32. Rohde LE, Ducharme A, Arroyo LH, Aikawa M, Sukhova GH, Lopez-Anaya A, et al. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 1999;99:3063-70.
33. Ducharme A, Frantz S, Aikawa M, Rabkin E, Lindsey M, Rohde LE, et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 2000;106:55-62.
34. Creemers EEJM, Cleutjens JPM, Smits JFM, Daemen MJAP. Matrix metalloproteinase inhibition after myocardial infarction. A new approach to prevent heart failure? Circ Res 2001;89:201-10.
35. Ye S. Polymorphism in matrix metalloproteinase gene promotors: Implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol 2000;19:623-9.
36. Zhang B, Herrmann SM, Eriksson P, de Maat M, Evans A et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Ciculation 1999;99:1788-94.
37. Hirohata S, Kusachi S, Murakami M, Marakami T, Sano I, Watanabe T et al. Time dependent alterations of serum matrix metalloproteinase-1 and metalloproteinase-1 tissue inhibitor after successful reperfusion of myocardial infarction. Heart 1997;78:278-84.